Who are AZD9550's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): P-3073, TGR-1202, GDC 695, AD-221, GFH375.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd9550.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AZD9550 — Competitive Intelligence Brief

AZD9550 (AZD9550) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K delta inhibitor. Area: Oncology.

phase 2 PI3K delta inhibitor PI3K delta (p110δ) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD9550 (AZD9550) — AstraZeneca. AZD9550 is a small molecule that acts as a selective and potent inhibitor of the PI3K delta (p110δ) subunit.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZD9550 TARGET	AZD9550	AstraZeneca	phase 2	PI3K delta inhibitor	PI3K delta (p110δ)
P-3073	P-3073	Polichem S.A.	phase 3	PI3K delta inhibitor	PI3K delta
TGR-1202	TGR-1202	Vanderbilt-Ingram Cancer Center	phase 3	PI3K delta inhibitor	PI3K delta
GDC 695	GDC 695	Balmoral Medical company	phase 3	PI3K delta inhibitor	PI3K delta (p110δ)
AD-221	AD-221	Addpharma Inc.	phase 3	PI3K delta inhibitor	PI3K delta
GFH375	GFH375	Genfleet Therapeutics (Shanghai) Inc.	phase 3	PI3K delta inhibitor	PI3K delta

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K delta inhibitor class)

AstraZeneca · 8 drugs in this class
Astellas Pharma Global Development, Inc. · 2 drugs in this class
Astellas Pharma Europe B.V. · 2 drugs in this class
Astellas Pharma Inc · 1 drug in this class
Axikin Pharmaceuticals, Inc. · 1 drug in this class
Balmoral Medical company · 1 drug in this class
Calluna Pharma AS · 1 drug in this class
Genfleet Therapeutics (Shanghai) Inc. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
InventisBio Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD9550 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd9550. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab